What you could know:

– Pangea Biomed, the startup behind the world’s most superior most cancers response predictor, ENLIGHT, pronounces a strategic collaboration with the Sharett Institute of Oncology and the Hadassah Most cancers Analysis Institute (HCRI) at Hadassah College Hospital Ein-Kerem and Ultima Genomics, the developer of a revolutionary structure for high-throughput genomic sequencing.

– This partnership goals to enhance the accuracy and effectiveness of stable tumor therapy predictions by superior genetic and transcriptomic profiling.

Pangea Biomed and Hadassah Partnership Enhances Precision Oncology for Sufferers with Stable Tumors

Based in 2018, Pangea Biomed developed ENLIGHT, the world’s most superior multi-cancer, multi-therapy response predictor. By leveraging machine studying and deep RNA evaluation, Pangea Biomed maps tumor molecular signatures to dynamically and adaptively personalize most cancers care. The corporate’s mission is to deliver efficient precision oncology to most cancers sufferers, advance oncology drug improvement, and allow oncologists to extend therapy success.

Stable tumors, together with breast, lung, prostate, and kidney cancers, account for about 90% of grownup human cancers. These tumors are difficult to deal with on account of their genetic heterogeneity and potential for metastasis. Efficient therapy usually requires a mixture of surgical procedure, radiation, chemotherapy, focused remedy, and immunotherapy, tailor-made to the precise genetic profile of the tumor.

In a significant initiative led by Hadassah, practically all sufferers with stable tumors present process biopsy on the Sharett Institute of Oncology will obtain complete genetic profiling with FoundationOne, a broad, tissue-based companion DNA diagnostic check. This profiling will inform remedy decisions. Pangea Biomed will use RNA knowledge acquired by Ultima Genomics and whole-slide histopathology scans as inputs to its AI-driven ENLIGHT platform. The ensuing ENLIGHT reviews, mixed with Hadassah’s medical output and analytics, are anticipated to enhance therapy selections for these sufferers.

The partnership between Pangea Biomed and Hadassah contains a number of key elements:

– Hadassah will present important organic samples and conduct in depth affected person follow-ups.

– Hadassah specialists will conduct in-depth analyses of the dataset, together with DNA check outcomes, medical knowledge, and affected person info.

– Hadasit, the Expertise Switch Firm and innovation arm of Hadassah Hospitals, facilitates this collaboration and indicators the settlement on behalf of Hadassah.

– This partnership builds on Pangea Biomed’s present collaboration with researchers at Hadassah to research knowledge from sufferers handled with immunotherapy on the Sharett Institute of Oncology. The outcomes, which demonstrated that ENLIGHT Matching Scores outperformed customary biomarkers, have been not too long ago introduced on the ASCO 2024 Annual Assembly.

“This collaboration marks a big step ahead within the struggle in opposition to stable tumors,” mentioned Tuvik Beker, CEO of Pangea Biomed. “By integrating complete DNA, RNA and imaging knowledge, we’re creating an unprecedented dataset that won’t solely instantly profit sufferers but additionally stimulate numerous future analysis efforts and medical trials.”

The collaboration is meant as a long-term, multi-year undertaking to supply ENLIGHT reviews for greater than 2,000 sufferers yearly.